ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Surgical Oncologists Honor HHS Secretary

March 22, 2002

In Brief: Adamson is Acting Frederick Director; Fischinger Heads Hollings Center; ASCO Has New Exec. Dir.

February 12, 1993

Emory, Children’s Strengthen Ties

May 25, 2001

Another Potti Paper Retracted

September 16, 2011

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

Gallo, Four Others Share Lasker Award

November 19, 1982